ContractLicensing Agreement • December 17th, 2021 • Genfit S.A. • Biological products, (no disgnostic substances)
Contract Type FiledDecember 17th, 2021 Company IndustryGENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
ContractLicensing Agreement • December 16th, 2021
Contract Type FiledDecember 16th, 2021GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership